Glucagon-like Peptide-1: New Target for Treating Non-Alcoholic Fatty Liver Disease?

Liu Ye,Hong Tianpei,Wei Rui,Yang Jin
DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2015.05.002
2015-01-01
Abstract:Recent studies have demonstrated an association of glucagon-like peptide-1 (GLP-1) signaling defect with non-alcoholic fatty liver disease (NAFLD).Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes,resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism,and the suppression of oxidative stress in liver cells.Moreover,GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.
What problem does this paper attempt to address?